FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBioxytran, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIXT
Bioxytran, Inc. Stock AnalysisComprehensive stock analysis for Bioxytran, Inc. (BIXT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBIXT
BIXT
Bioxytran, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIXT
  1. Home
  2. Stocks
  3. Bioxytran, Inc.

Bioxytran, Inc.

🇺🇸BIXT•OTC

Bioxytran, Inc.

🇺🇸BIXT•OTC
Market cap
$3.65M

Your view on BIXT

Mkt Cap
$3.65M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Bioxytran, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
David Platt
Headquarters
233 Needham Street, Newton, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
David Platt
Headquarters
233 Needham Street, Newton, MA, US
Description

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.

The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.

It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Bioxytran, Inc.. Starting points for Bioxytran, Inc.: EPS -$0.03, beta 2.08 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Bioxytran, Inc.. Bioxytran, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Bioxytran, Inc.. Trailing twelve-month EPS for Bioxytran, Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Bioxytran, Inc.. Bioxytran, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BIXT20 companies
Compare BIXT with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BETRFBetterLife Pharma Inc.HealthcareBiotechnology$6.4M
BVAXFBioVaxys Technology Corp.HealthcareBiotechnology$3.1M
BZYRBurzynski Research Institute, Inc.HealthcareMedical - Pharmaceuticals$3.4M
CPMVMosaic ImmunoEngineering Inc.HealthcareBiotechnology$2.9M
GLWLFGlow Lifetech Corp.HealthcareBiotechnology$6.7M
KNBIFKane Biotech Inc.HealthcareBiotechnology$4.6M
MYNDFMYND Life Sciences Inc.HealthcareBiotechnology$657,843
NSHSFNanoSphere Health Sciences Inc.HealthcareBiotechnology$102,752
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ERASErasca, Inc.HealthcareNASDAQ$4.8B
ERNAErnexa Therapeutics Inc.HealthcareNASDAQ$2.3M
ERNAWErnexa Therapeutics Inc. WarrantsHealthcareNASDAQ$201,824
ESLAEstrella Immunopharma, Inc.HealthcareNASDAQ$14.1M
ESLAWEstrella Immunopharma, Inc.HealthcareNASDAQ$19.4M
EVAXEvaxion Biotech A/SHealthcareNASDAQ$14.2M
EVFMEvofem Biosciences, Inc.HealthcareOTC$1.2M
EVGNEvogene Ltd.HealthcareNASDAQ$2.7M
EVLOEvelo Biosciences, Inc.HealthcareOTC$1,898
EVMNEvommune, Inc.HealthcareNYSE$291.1M
EWTXEdgewise Therapeutics, Inc.HealthcareNASDAQ$4.3B
EXELExelixis, Inc.HealthcareNASDAQ$16.2B
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Bioxytran, Inc. executives and directors. Shares of Bioxytran, Inc. have traded between $0.03 and $0.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Bioxytran, Inc.. Coverage tracks Bioxytran, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Bioxytran, Inc.

BIXT AnalysisWeak
Past
1
Growth
2
Health
1
Profit
1
Value
1